Research Projects

The rapid rise of infectious diseases has become one of the biggest potential threats to human health, particularly because of the emergence of resistance to current antimicrobial drugs. In this context, there is a worldwide interest in the discovery of new antimicrobial agents with increased effectiveness, especially on microbial strains resistant to all current antibiotics. N- and/or S-containing condensed heterocycles are common structural motifs in a variety of biological activities and therapeutically useful compounds leading to potential applications in treating antituberculosis, human 5-HT5A Receptor binding inhibition, antitumor, anti-infective, anti-osteoarthritis, antibacterial, and antifungal drugs. In the current pandemic situation, we all go through the bad phase and realize how a virus can disturb our whole body system by viral attacks as well as by different microbial attacks. So there is a great need for a drug that can act as antiviral agents together with antimicrobial agents. To meet the needs of the competitive drug market, pharmaceutical companies have recently been driven to discover new ways to supply more efficient technologies against the backdrop of a difficult economic and regulatory climate. This project aims to provide a potential heterocyclic drug, containing a 1,2,3-triazole based bridging, clicked scaffold in the drug discovery, which has frequently been used as a bridge to combine different cytotoxic active scaffolds to design new chemical entities. To provide it with better biocompatibility and biodegradability, we are also trying to prepare biowaste-generated carbon quantum dots (CQDs) and their heterocyclic drugs functionalized CQDs.